Swiss National Bank Portfolio holdings
The Swiss National Bank (SNB), founded in 1907 and headquartered in Zurich with an office in Bern, is Switzerland’s central bank, responsible for conducting monetary policy, issuing the Swiss franc, and ensuring price stability, while uniquely managing a massive investment portfolio. Unlike most central banks, the SNB is a joint-stock company with shares traded on the SIX Swiss Exchange, owned roughly 55% by public entities like cantons and 45% by private investors, yet it operates independently under federal oversight. It holds over $800 billion in foreign currency reserves as of late 2024—invested in global equities, bonds, and gold—to manage the franc’s value, famously intervening in markets to prevent excessive appreciation, as seen with the 2015 abandonment of the euro peg. Led by Chairman Thomas Jordan until his planned exit in September 2024, the SNB balances its dual role as a monetary authority and a significant global investor, influencing both Swiss and international financial stability.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$114M |
| 2 |
BKI
Black Knight, Inc. Common Stock
BKI
|
+$31.3M |
| 3 |
PARA
Paramount Global Class B
PARA
|
+$26.4M |
| 4 |
Tyler Technologies
TYL
|
+$25M |
| 5 |
Brown & Brown
BRO
|
+$18.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$249M |
| 2 |
CELG
Celgene Corp
CELG
|
+$231M |
| 3 |
Microsoft
MSFT
|
+$171M |
| 4 |
Alibaba
BABA
|
+$140M |
| 5 |
Amazon
AMZN
|
+$99.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.49% |
| 2 | Healthcare | 14.66% |
| 3 | Consumer Discretionary | 11.66% |
| 4 | Communication Services | 10.19% |
| 5 | Industrials | 9.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2351
Global Industrial
GIC
$1.5B
| $632K | ﹤0.01% |
25,100
+800
| +3% | +$18.7K |
|
2352
RPC Inc
RES
$1.4B
| $628K | ﹤0.01% |
119,900
| – | – |
|
2353
Funko
FNKO
$332M
| $623K | ﹤0.01% |
+36,300
| New | +$593K |
|
|
ACH
2354
Accendra Health
ACH
$96.5M
| $623K | ﹤0.01% |
+120,500
| New | +$774K |
|
2355
Future Fuel
FF
$279M
| $622K | ﹤0.01% |
50,209
+2,300
| +5% | +$27.4K |
|
2356
TORM
TRMD
$2.93B
| $622K | ﹤0.01% |
55,601
| – | – |
|
2357
Energy Recovery
ERII
$394M
| $618K | ﹤0.01% |
63,100
+2,900
| +5% | +$26.7K |
|
|
ROCC
2358
DELISTED
Ranger Oil Corporation Class A Common Stock
ROCC
| $613K | ﹤0.01% |
20,200
+500
| +3% | +$13.3K |
|
|
MOBL
2359
DELISTED
MobileIron, Inc.
MOBL
| $613K | ﹤0.01% |
126,100
+3,800
| +3% | +$20.2K |
|
2360
Omega Flex
OFLX
$302M
| $612K | ﹤0.01% |
5,700
| – | – |
|
2361
Quanterix
QTRX
$124M
| $612K | ﹤0.01% |
25,900
| – | – |
|
|
ORBC
2362
DELISTED
ORBCOMM, Inc.
ORBC
| $611K | ﹤0.01% |
145,100
+5,700
| +4% | +$24.4K |
|
2363
Health Catalyst
HCAT
$132M
| $607K | ﹤0.01% |
+17,500
| New | +$579K |
|
|
CAMP
2364
DELISTED
CalAmp Corp.
CAMP
| $607K | ﹤0.01% |
2,757
| – | – |
|
2365
Arlo Technologies
ARLO
$1.59B
| $604K | ﹤0.01% |
143,392
+5,800
| +4% | +$19.9K |
|
2366
Franklin Covey
FC
$235M
| $603K | ﹤0.01% |
+18,700
| New | +$678K |
|
|
AKCA
2367
DELISTED
Akcea Therapeutics Inc
AKCA
| $603K | ﹤0.01% |
35,600
+800
| +2% | +$14.9K |
|
|
BSTC
2368
DELISTED
BioSpecifics Technologies Corp.
BSTC
| $598K | ﹤0.01% |
10,500
+300
| +3% | +$15.9K |
|
2369
Caesarstone
CSTE
$104M
| $595K | ﹤0.01% |
39,500
+1,200
| +3% | +$19.3K |
|
2370
KRONOS Worldwide
KRO
$963M
| $595K | ﹤0.01% |
44,400
+2,400
| +6% | +$31.4K |
|
2371
Surgery Partners
SGRY
$1.96B
| $593K | ﹤0.01% |
37,900
+1,500
| +4% | +$17K |
|
2372
Gossamer Bio
GOSS
$88.9M
| $592K | ﹤0.01% |
37,900
+1,100
| +3% | +$22.2K |
|
|
VSLR
2373
DELISTED
VIVINT SOLAR, INC.
VSLR
| $592K | ﹤0.01% |
81,500
+3,800
| +5% | +$26.8K |
|
|
EIGI
2374
DELISTED
Endurance International Group Holdings, Inc.
EIGI
| $591K | ﹤0.01% |
125,800
+5,300
| +4% | +$21.8K |
|
2375
FLEX LNG
FLNG
$1.58B
| $590K | ﹤0.01% |
56,964
+1,595
| +3% | +$15.9K |
|
Similar funds
Swiss National Bank's Q4 2019 Portfolio in Review
As of Q4 2019, Swiss National Bank held 2,602 positions worth $97.5B, up 3.6% from $94.1B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Swiss National Bank withdrew a net $3.98B in Q4 2019, closing 96 positions and reducing 725 holdings. Its most notable exit was Celgene Corp, an estimated $231M position sold in full.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 20% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Swiss National Bank opened a new position in Match Group worth $14.7M.
- Swiss National Bank's largest Q4 2019 buy was Match Group: 179,200 shares worth $14.7M.
- Swiss National Bank added most to Bristol-Myers Squibb in Q4 2019, an estimated $114M increase.
- Swiss National Bank's biggest Q4 2019 reduction was Apple, cutting an estimated $249M.
- Swiss National Bank fully exited Celgene Corp in Q4 2019, selling an estimated $231M.
- Swiss National Bank's ten largest holdings make up 19% of its $97.5B portfolio in Q4 2019.
- Swiss National Bank opened 82 new positions and closed 96 in Q4 2019.
- Swiss National Bank's portfolio value rose 3.6% quarter-over-quarter to $97.5B.
Based on Swiss National Bank's 13F filing for Q4 2019, filed 6 Feb 2020.